FTI 2153
Latest Information Update: 29 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial sources
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Jul 1999 New profile
- 12 Jul 1999 Preclinical development for Cancer in USA (Unknown route)